☆
4.7
Letter
Re: Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years French temporary authorisation for use (ATU) and early access to therapeutic innovations: there are still many patients slipping through the cracks
EUROPEAN JOURNAL OF CANCER (2021)
导出引文
没有可用的引文
分享论文
评价这篇论文
主要评分表示论文的整体质量水平。次要评分独立反映论文的优点或缺点。
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started